Anti-mutated citrullinated vimentin (anti-MCV) and anti-65kDa heat shock protein (anti-hsp65): New biomarkers in ankylosing spondylitis

Joint Bone Spine

Volumn 79, Issue 1, 2012, Pages 63-66

  Bodnár, Nóra ^a   Szekanecz, Zoltán ^a   Prohászka, Zoltán ^b   Kemény Beke, Ádám ^a   Némethné Gyurcsik, Zsuzsanna ^a   Gulyás, Katalin ^a   Lakos, Gabriella ^a,c   Sipka, Sándor ^a   Szántó, Sándor ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Thera Test laboratories Inc   (United States)

Author keywords

ACPA; Ankylosing spondylitis; Anti hsp65; Anti MCV

Indexed keywords

ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HEAT SHOCK PROTEIN 65 ANTIBODY; HLA B27 ANTIGEN; MUTATED CITRULLINATED VIMENTIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS METRIC INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PAIN ASSESSMENT; RATING SCALE; SMOKING; VISUAL ANALOG SCALE;

ADULT; AGED; AUTOANTIBODIES; BACTERIAL PROTEINS; BIOLOGICAL MARKERS; CHAPERONIN 60; CITRULLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SPONDYLITIS, ANKYLOSING; VIMENTIN;

EID: 84855693531     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.03.010     Document Type: Article

References (39)

1. Salvarani C., Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009, 15:2449-2455.
2. Vegvari A., Szabo Z., Szanto S., et al. The genetic background of ankylosing spondylitis. Joint Bone Spine 2009, 76:623-628.
3. Rudwaleit M., Landewe R., van der Heijde D., et al. The development of assessment of Spondylo Arthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009, 68:770-776.
4. Rudwaleit M., Schwarzlose S., Hilgert E.S., et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008, 67:1276-1281.
5. Holers V.M. Antibodies to citrullinated proteins: pathogenic and diagnostic significance. Curr Rheumatol Rep 2007, 9:396-400.
6. Szekanecz Z., Soos L., Szabo Z., et al. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?. Clin Rev Allergy Immunol 2008, 34:26-31.
7. Soos L., Szekanecz Z., Szabo Z., et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007, 34:1658-1663.
8. Klareskog L., Widhe M., Hermansson M., et al. Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 2008, 20:300-305.
9. Migliorini P., Pratesi F., Tommasi C., et al. The immune response to citrullinated antigens in autoimmune diseases. Autoimmun Rev 2005, 4:561-564.
10. Sebbag M., Chapuy-Regaud S., Auger I., et al. Clinical and pathophysiological significance of the autoimmune response to citrullinated proteins in rheumatoid arthritis. Joint Bone Spine 2004, 71:493-502.
11. Gyetvai A., Szekanecz Z., Soos L., et al. New classification of the shared epitope in rheumatoid arthritis: impact on the production of various anti-citrullinated protein antibodies. Rheumatology (Oxford) 2010, 49:25-33.
12. Ding B., Padyukov L., Lundstrom E., et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum 2009, 60:30-38.
13. Schellekens G.A., Visser H., de Jong B.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163.
14. Kinloch A., Tatzer V., Wait R., et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R1421-1429.
15. Snir O., Widhe M., von Spee C., et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 2009, 68:736-743.
16. Nielen M.M., van der Horst A.R., van Schaardenburg D., et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005, 64:1199-1204.
17. Dejaco C., Duftner C., Klotz W., et al. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFalpha treatment response in rheumatoid arthritis. Scand J Rheumatol 2009, 38:66-67.
18. Innala L., Kokkonen H., Eriksson C., et al. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides. J Rheumatol 2008, 35:1002-1008.
19. Szodoray P., Szabo Z., Kapitany A., et al. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010, 9:140-143.
20. van der Helm-van Mil A.H., Wesoly J.Z., Huizinga T.W. Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 2005, 17:299-304.
21. Klareskog L., Padyukov L., Lorentzen J., et al. Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2006, 2:425-433.
22. Vossenaar E.R., Despres N., Lapointe E., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:R142-150.
23. Coenen D., Verschueren P., Westhovens R., et al. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007, 53:498-504.
24. Dejaco C., Klotz W., Larcher H., et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R119.
25. Mathsson L., Mullazehi M., Wick M.C., et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008, 58:36-45.
26. Poulsom H., Charles P.J. Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis. Clin Rev Allergy Immunol 2008, 34:4-10.
27. Beltrami A., Rossmann M., Fiorillo M.T., et al. Citrullination-dependent differential presentation of a self-peptide by HLA-B27 subtypes. J Biol Chem 2008, 283:27189-27199.
28. Damjanovska L., Thabet M.M., Levarht E.W., et al. The diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Ann Rheum Dis 2010, 69:730-732.
29. van Halm V.P., Slot M.C., Nurmohamed M.T., et al. Antibodies against human 60kDa heat shock protein are not associated with cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:590-594.
30. Tishler M., Shoenfeld Y. Anti-heat-shock protein antibodies in rheumatic and autoimmune diseases. Semin Arthritis Rheum 1996, 26:558-563.
31. Tsoulfa G., Rook G.A., Bahr G.M., et al. Elevated IgG antibody levels to the mycobacterial 65-kDa heat shock protein are characteristic of patients with rheumatoid arthritis. Scand J Immunol 1989, 30:519-527.
32. Moreland L.W., Koopman W.J. Infection as a cause of arthritis. Curr Opin Rheumatol 1991, 3:639-649.
33. Pope R.M., Wallis R.S., Sailer D., et al. T cell activation by mycobacterial antigens in inflammatory synovitis. Cell Immunol 1991, 133:95-108.
34. McLean I.L., Archer J.R., Cawley M.I., et al. Specific antibody response to the mycobacterial 65kDa stress protein in ankylosing spondylitis and rheumatoid arthritis. Br J Rheumatol 1990, 29:426-429.
35. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
36. Pedersen M., Jacobsen S., Garred P., et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 2007, 56:1446-1453.
37. Prohaszka Z., Duba J., Horvath L., et al. Comparative study on antibodies to human and bacterial 60kDa heat shock proteins in a large cohort of patients with coronary heart disease and healthy subjects. Eur J Clin Invest 2001, 31:285-292.
38. Klareskog L., Ronnelid J., Lundberg K., et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008, 26:651-675.
39. Tilleman K., Van Steendam K., Cantaert T., et al. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology (Oxford) 2008, 47:597-604.